Pages that link to "Q37920867"

The following pages link to Pharmacokinetics and metabolism of mitoxantrone. A review (Q37920867):

Displaying 41 items.

• Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action (Q27693179) (← links)
• Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (Q28265412) (← links)
• Preparation, characterization, and in vivo evaluation of mitoxantrone-loaded, folate-conjugated albumin nanoparticles (Q33677766) (← links)
• Pharmacology of Anticancer Drugs in the Elderly Population (Q35579412) (← links)
• Mitoxantrone: a review of its use in multiple sclerosis (Q35747877) (← links)
• A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding (Q35888381) (← links)
• Mitoxantrone (Novantrone) in multiple sclerosis: new insights (Q36107235) (← links)
• Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells (Q36641685) (← links)
• Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer (Q36657495) (← links)
• Current and future treatment approaches for neuromyelitis optica (Q37892874) (← links)
• Mitoxantrone, More than Just Another Topoisomerase II Poison. (Q38569206) (← links)
• Treatment of multiple sclerosis during pregnancy - safety considerations (Q38883520) (← links)
• The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs (Q39231153) (← links)
• Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer (Q39455318) (← links)
• 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice (Q39600534) (← links)
• Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. (Q39716863) (← links)
• Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro (Q39718646) (← links)
• Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia (Q41120664) (← links)
• Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis (Q41813215) (← links)
• Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes (Q42014456) (← links)
• Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis (Q43481246) (← links)
• Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma (Q43658195) (← links)
• Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer (Q44423321) (← links)
• Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents (Q44593854) (← links)
• Preparation, characterization, and stability of liposome-based formulations of mitoxantrone (Q46385842) (← links)
• In vitro evaluation of acute effects of mitoxantrone (Novantrone) in rat and guinea pig atria (Q46748406) (← links)
• Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study (Q46876309) (← links)
• Mitoxantrone suppresses vascular smooth muscle cell (VSMC) proliferation and balloon injury-induced neointima formation: An in vitro and in vivo study (Q47146916) (← links)
• Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy (Q48354981) (← links)
• Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors (Q48724165) (← links)
• Liposomal Drug Delivery Systems and Anticancer Drugs. (Q52584651) (← links)
• Exploring the Effects of Glycosylation and Etherification of the Side Chains of the Anticancer Drug Mitoxantrone. (Q53397800) (← links)
• Anthracycline antibiotics derivate mitoxantrone-Destructive sorption and photocatalytic degradation. (Q55005006) (← links)
• Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment (Q58229934) (← links)
• Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies (Q72362556) (← links)
• Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats (Q77716996) (← links)
• Topoisomerase II inhibitors (Q80510502) (← links)
• Topoisomerase II inhibitors (Q81086247) (← links)
• Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations (Q89811537) (← links)
• Pulsatile Chemotherapeutic Delivery Profiles Using Magnetically Responsive Hydrogels (Q90301892) (← links)
• Studies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone: PS177 (Q91656221) (← links)